TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TELA Bio ( (TELA) ) has provided an update.
On October 4, 2025, TELA Bio, Inc. announced the resignation of Lisa Colleran from its Board of Directors, where she also served on the Nominating and Corporate Governance Committee and the Audit Committee. Her resignation was not due to any disagreements with the company’s operations or policies. Subsequently, on October 7, 2025, the company appointed Dr. Betty Jo Rocchio to the Board, effective October 9, 2025. Dr. Rocchio, who has an extensive background in nursing leadership, will serve as a Class I director until the 2026 Annual Meeting of Stockholders. Her appointment is aligned with TELA Bio’s non-employee director compensation policy, which includes an initial equity award and an annual base retainer.
The most recent analyst rating on (TELA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
Spark’s Take on TELA Stock
According to Spark, TipRanks’ AI Analyst, TELA is a Neutral.
TELA Bio’s stock score is primarily influenced by its financial performance challenges, including negative profitability and cash flows. Despite strong revenue growth and improved gross margins highlighted in the earnings call, the technical indicators suggest a bearish trend, and the valuation remains unattractive due to ongoing losses.
To see Spark’s full report on TELA stock, click here.
More about TELA Bio
Average Trading Volume: 89,200
Technical Sentiment Signal: Strong Sell
Current Market Cap: $62.2M
For an in-depth examination of TELA stock, go to TipRanks’ Overview page.